Publications

Scroll Down

2024

  1. Gupta P, Goswami SG, Kumari G, Saravanakumar V, Bhargava N, Rai AB, Singh P, Bhoyar RC, Arvinden VR, Gunda P, Jain S, Narayana VK, Deolankar SC, Prasad TSK, Natarajan VT, Scaria V, Singh S, Ramalingam S (2024). Development of pathophysiologically relevant models of sickle cell disease and β-thalassemia for therapeutic studies. Nat Commun.15(1):1794. doi: 10.1038/s41467-024-46036-x
  2. Sahel DK, Goswami SG, Jatyan R, Kumari A, Tharmatt A, Singh V, , Mohanthy S, Mittal. S, Mittal A, Ramalingam S, Chitkara D. (2024). cRGD-modified hybrid lipopolymeric nanoplexes for gene editing in the posterior segment of the eye. Int J Biol Macromol. https://doi.org/10.1016/j.ijbiomac.2024.132426.
  3. Sarangi P, Kumar N, Sambasivan R, Ramalingam S, Amit S, Chandra D, Rao JG (2024). AAV-mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B. Thromb Res. https://doi.org/10.1016/j.thromres.2024.04.031.
  4. Marothia M, Behl A, Mourya P Monika Saini M, Garg S, Kumari G, Biswas S, Shoaib R, Akshay Munjal1, Anand S, Kahlon AK, Upadhyay P, Gupta P, Biswas S, Bhowmick IP, Shevtsov M, Pati S, Ramalingam S, Ranganathan A, Singh S (2024). Targeting PfProhibitin 2 – Hu-Hsp70A1A complex as a unique approach towards malaria vaccine development. iScience. https://doi.org/10.1016/j.isci.2024.109918

2023

  1. Gupta, R, Thakur P, Bhoyer R, Saravanakumar V, Varma N, Goswami S, Nafiz M, Iyer A, Vignesh H, Soni R, Bhargava N, Gunda S, Jain S, Gupta V, Sivasubbu S, Scaria V and Ramalingam S (2023). Scalable noninvasive amplicon-based precision sequencing (SNAPseq) for genetic diagnosis and screening of β-thalassemia and sickle cell disease using a next-generation sequencing platform. Front Mol Biosci. doi: 10.3389/fmolb.2023.1244244.
  2. Laura HM, Sambasivam V, Amanda L. Hughes, Annaluru N, Ramalingam S, Fanfani V, Lobzaev E. et al. (2023). Consequences of a telomerase-related fitness defect and chromosome substitution technology in yeast synIX strains. Cell Genomics. https://doi.org/10.1016/j.xgen.2023.100419
  3. Ramalingam S, Kumar A, Krug S, Mohan H, Rao DN, Bishai WR, Chandrasegaran S (2023) CRISPR correction of GBA mutation in hiPSCs restores normal function to Gaucher macrophages and increases their susceptibility to Mycobacterium tuberculosis. J Infect Dis. May 9:jiad141. doi: 10.1093/infdis/jiad141.
  4. Jaganathan D, Rajakani R, Doddamani D, Saravanan D, Pulipati S, Hari Sundar G V, Sellamuthu G, Jayabalan S, Kumari K, Parthasarathy P, S P, Ramalingam S, Shivaprasad PV, Venkataraman G. A conserved SNP variation in the pre-miR396c flanking region in Oryza sativa indica landraces correlates with mature miRNA abundance. Sci Rep. 2023 Feb 7;13(1):2195. doi: 10.1038/s41598-023-28836-1.
  5. Ala C, Joshi RP, Gupta P, Ramalingam S, Sankaranarayanan M (2023). Discovery of potent DNMT1 inhibitors against sickle cell disease using structural-based virtual screening, MM-GBSA and molecular dynamics simulation-based approaches. J Biomol Struct Dyn. 16:1-13. doi: 10.1080/07391102.2023.2199081.
  6. Sahel DK, Goswami SG, Jatyan R, Kumari A, Mittal A, Ramalingam S, Chitkara D (2023). Lipopolymeric nanocarrier enables effective delivery of CRISPR/Cas9 expressing plasmid. Macromol Rapid Commun. https://doi.org/10.1002/marc.202300101

2022

  1. Bhargava N, Thakur P, Muruganandam TP, Jaitly S, Gupta P, Lohani N, Goswami SG, Saravanakumar V, Bhattacharya SK, Jain S, Ramalingam S (2022). Development of an efficient single-cell cloning and expansion strategy for genome-edited induced pluripotent stem cells. Mol Biol Rep. 49(8): 7887-7898.
  2. Thakur P, Gupta P, Bhargava N, Soni R, Varma Gottumukkala N, Goswami SG, Kharya G, Saravanakumar V, Gunda P, Jain S, Dass J, Aggarwal M, Ramalingam S. (2022). A Simple, Cost-Effective, and Extraction-Free Molecular Diagnostic Test for Sickle Cell Disease Using a Noninvasive Buccal Swab Specimen for a Limited-Resource Setting. Diagnostics. 21;12(7):1765.
  3. Sahel DK, Salman M, Azhar M, Goswami SG, Singh V, Dalela M, Mohanty S, Mittal A, Ramalingam S, Chitkara D (2022). Cationic lipopolymeric nanoplexes containing the CRISPR/Cas9 ribonucleoprotein for genome surgery. J Mater Chem B. doi: 10.1039/d2tb00645f.
  4. Yadav R, Devi S, Ramalingm S, Arya R (2022). Effect of GNE mutation on protein aggregate phenomenon: therapeutic challenges in ultra-rare GNE Myopathy. Int J Biochem Cell Biol. doi: 10.1016/j.biocel.2022.106258.
  5. Gupta P, Jaitly S, Thakur P, Goswami SG, Bhargava N, Ramalingam S (2022). Genome‐Editing Applications in Stem Cell Engineering and Regenerative Medicine. Genome Edit Drug Discov.  https://doi.org/10.1002/9781119671404.ch17.
  6. Kumari G, Rex DAB, Goswami S, Mukherjee S, Biswas S, Maurya P, Jain R, Garg S, Prasad TSK, Pati S, Ramalingam S, Mohandas N, Singh S (2022). Dynamic Palmitoylation of Red Cell Membrane Proteins Governs Susceptibility to Invasion by the Malaria Parasite, Plasmodium falciparum. ACS Infect Dis. doi: 10.1021/acsinfecdis.2c00199
  7. Dey SS, Ramalingam S, Taneja B (2022). A dual-plasmid based CRISPR/Cas9-mediated strategy enables targeted editing of pH regulatory gene paaC in a clinical isolate Trichophyton rubrum. J Fungi (accepted).
  8. Arumugam P, Chauhan M, Rajeev T, Chakraborty R, Bisht K, Madan M, Shankaran D, Ramalingam S, Gandotra S and Rao V (2022) The mitochondrial gene-CMPK2 functions as a rheostat for macrophage homeostasis. Front Immunol. 13:935710. doi: 10.3389/fimmu.2022.935710.

2021

  1. Sahana S, Sivadas A, Mangla M, Jain A, Bhoyar RM, Pandare K,..Mukerji M, Ramalingam S, Kumar B, Scaria V, Sivasubbu S (2021). Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes. Pharmacogenomics. doi: 10.2217/pgs-2021-0028.
  2. Jain A, Bhoyar RC, Pandhare K, Mishra A, Sharma D, Imran M, Senthivel V, , Soraisham R, Yadav R, Devi YS, Gupta A, Mukerji M, Ramalingam S, B K B, Scaria V, Sivasubbu S. Genetic epidemiology of autoinflammatory disease variants in Indian population from 1029 whole genomes. J Genet Eng Biotechnol. 2021 Dec 14;19(1):183.
  3. Kumar A, Ramalingam S, Rao DNR, Chandrasegaran S (2021). Genome Editing Revolution in Life Sciences. Resonance. DOI: https://doi.org/10.1007/s12045-021-1195-z
  4. Thakur P, Bhargava N, Jaitly S, Gupta P, Saroja, Padma P, Jain S, Bhattacharya S, Ramalingam S (2021). Establishment and characterization of induced pluripotent stem cell line (IGIBi002-A) from a β-thalassemia patient with IVS1-5 mutation by non-integrating reprogramming approach. Stem Cell Res. doi.org/10.1016/j.scr.2020.102124.

2020

  1. Jain A, Bhoyar RC, Pandhare K, Mishra A, Sharma D, Imran M, Senthivel V, Mukerji M, Ramalingam S, Kumar B, Scaria V, Sivasubbu S (2020). IndiGenomes: a comprehensive resource of genetic variants from over 1000 Indian genomes. Nucleic Acids Res. doi: 10.1093/nar/gkaa923.
  2. Chakraborty D, Maiti S, Azhar M, Paul D, Acharya S, Phutela R, Hussain A, Sinha D, Kumar M, Rauthan R, Aich M, Sharma S, Sharma N, Mishra A, Jain S, Ray A, Ramalingam S (2020). Highly Precise ex vivo correction of sickle cell anemia mutation in patient cells using FnCas9. Mol Ther. 28(4). 105.
  3. Narasimhan I, Murali A, Subramanian K, Ramalingam S, Parameswaran S (2020). Autosomal dominant retinitis pigmentosa with toxic gain of function: Mechanisms and therapeutics. Eur J Ophthalmol. doi: 10.1177/1120672120957605.

2019

  1. Acharya S, Mishra A, Paul D, Ansari AH, Azhar M, Kumar M, Rauthan R, Sharma N, Aich M, Sinha D, Sharma S, Jain S, Ray A, Jain S, Ramalingam S, Maiti S, Chakraborty D. (2019) Francisella novicida Cas9 interrogates genomic DNA with very high specificity and can be used for mammalian genome editing. Proc Natl Acad Sci U S A. 15;116(42):20959-20968.
  2. Bajaj A, Methew S, Vellarikkal SK, Sivadas A, Bhoyar RC, Joshi K, Jain A, Verma, A, Jayaran A, Kumar RA, Seeralar AT, Gupta A, Achal K, The GuaRDIAN consortium, Ramalingam S,.Sharma YK, Brahmachari SK, Scaria A, Sivasubbu S (2019). Genomics of rare genetic diseases—experiences from India. Human Genomics. 13, 52.
  3. Ramalingam S and Thangaval S (2019) CRISPR-Cas9 probing of infectious disease and genetic disorders. The Ind J of Ped doi.org/10.1007/s12098-019-03037-9.
  4. Bhargava N, Jaitly S, Goswami S, Jain S, Chakarborty D, Ramalingam S (2019) Generation and characterization of induced pluripotent stem cells from a sickle cell anemia patient with homozygous β-globin mutation. Stem Cell Res 14;39:101484.

2018

  1. Lohani N, Bhargava N, Munshi A, Ramalingam S (2018) Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders. J cell Physiol. 233 (6): 4563-4577.